Department of Internal Medicine, School of Medicine, Yale University, New Haven, Connecticut.
Yale Center for Outcomes Research and Evaluation (CORE), Yale-New Haven Health Systems, New Haven, Connecticut.
Health Serv Res. 2019 Feb;54(1):139-148. doi: 10.1111/1475-6773.13072. Epub 2018 Oct 17.
To estimate rates and national trends of initiation of new psychotropic medications without a psychiatric diagnosis and to identify demographic and clinical correlates independently associated with such use among US adults in outpatient settings.
Data were gathered from the 2006-2015 National Ambulatory Medical Care Survey (NAMCS), a nationally representative sample of office-based U.S. outpatient care. The sample was limited to adults aged 18 or older who received a new psychotropic drug prescription (n = 8618 unweighted).
Using a repeated cross-sectional design with survey sampling techniques, we estimated prescription initiation rates and national trends. Multivariable-adjusted logistic regression analysis was used to identify correlates independently associated with initiation of new psychotropic prescriptions without a psychiatric diagnosis.
DATA COLLECTION/EXTRACTION METHODS: Data were publicly available, and we extracted them from the Centers for Disease Control and Prevention website.
Altogether, at 60.4% of visits at which a new psychotropic prescription was initiated, no psychiatric diagnosis was recorded for the visit. Overall, the rate increased from 59.1% in 2006-2007 to 67.7% in 2008-2009 and then decreased to 52.0% in 2014-2015. Visits to psychiatrists were associated with very low odds of having no psychiatric diagnosis when compared to primary care visits (OR = 0.02; 95% CI, 0.01-0.04). Visits to non-psychiatric specialists showed 6.90 times greater odds of not having a psychiatric diagnosis when compared to primary care visits (95% CI, 5.38-8.86).
New psychotropic medications are commonly initiated without any psychiatric diagnosis, especially by non-psychiatrist physicians. Non-psychiatrists should document relevant diagnoses more vigilantly to prevent potentially inappropriate use or misuse.
评估美国门诊环境下成年人新精神药物起始治疗中无精神科诊断的使用率和国家趋势,并确定与该治疗方式相关的独立人口统计学和临床因素。
数据来自于 2006-2015 年全国门诊医疗调查(NAMCS),这是一项具有全国代表性的美国门诊医疗抽样调查。样本仅限于年龄在 18 岁或以上、接受新精神药物处方(n=8618 个未加权)的成年人。
我们采用重复的横断面设计和调查抽样技术,估计处方起始率和国家趋势。多变量调整的逻辑回归分析用于确定与无精神科诊断的新精神药物处方起始相关的独立相关因素。
数据收集/提取方法:数据是公开的,我们从疾病控制与预防中心网站提取数据。
总共在 60.4%的新精神药物处方起始就诊中,就诊时未记录精神科诊断。总体而言,该比率从 2006-2007 年的 59.1%上升到 2008-2009 年的 67.7%,然后下降到 2014-2015 年的 52.0%。与初级保健就诊相比,看精神科医生的就诊记录与无精神科诊断的可能性非常低(OR=0.02;95%CI,0.01-0.04)。与初级保健就诊相比,非精神科专家就诊无精神科诊断的可能性高 6.90 倍(95%CI,5.38-8.86)。
新的精神药物经常在没有任何精神科诊断的情况下开始使用,尤其是由非精神科医生开具。非精神科医生应更警惕地记录相关诊断,以防止潜在的不适当使用或滥用。